Last updated: August 18, 2026
Forteo, Eli Lilly’s teriparatide injection, has moved from a blockbuster osteoporosis product to a mature specialty medicine facing generic and therapeutic competition. Global revenue declined from roughly $1.5 billion in 2018 to below $1 billion by 2021 and continued to fall as generic teriparatide entered the U.S. market, payer controls intensified and newer anabolic osteoporosis drugs gained share. Forteo retains clinical value in patients at high fracture risk, but its commercial position is now defined by price erosion, limited patent protection and competition from Tymlos and Evenity.
What is Forteo and how does teriparatide work?
Forteo is a recombinant form of human parathyroid hormone fragment 1-34, known as teriparatide. It is administered by subcutaneous injection, generally at a dose of 20 micrograms once daily.
The FDA approved Forteo in 2002 for:
- Postmenopausal women with osteoporosis at high risk of fracture
- Men with primary or hypogonadal osteoporosis at high risk of fracture
- Men and women with osteoporosis associated with systemic glucocorticoid therapy
Teriparatide stimulates osteoblast activity and increases new bone formation. This differentiates Forteo from antiresorptive therapies such as bisphosphonates and denosumab, which primarily reduce bone resorption.
The product initially carried a boxed warning based on osteosarcoma findings in rats. The FDA removed the boxed warning in 2020 after reviewing long-term human safety data. The agency also removed the lifetime 24-month treatment limitation, although use beyond two years remains reserved for patients who continue to have a high fracture risk and lack suitable alternatives (U.S. Food and Drug Administration, 2020).
How large is the Forteo market?
Forteo participates in the global market for prescription osteoporosis therapies. The market includes oral bisphosphonates, injectable antiresorptive products, anabolic agents and newer sclerostin inhibitors.
The most commercially important competing products include:
| Product |
Active ingredient |
Company |
Therapeutic role |
| Forteo |
Teriparatide |
Eli Lilly |
Anabolic osteoporosis therapy |
| Tymlos |
Abaloparatide |
Radius Health, later under Teva commercial arrangements |
Anabolic osteoporosis therapy |
| Evenity |
Romosozumab |
Amgen and UCB |
Monthly anabolic and antiresorptive activity |
| Prolia |
Denosumab |
Amgen |
Injectable antiresorptive therapy |
| Reclast |
Zoledronic acid |
Novartis originator, generic versions available |
Annual intravenous bisphosphonate |
| Fosamax and generics |
Alendronate |
Merck originator, multiple generic manufacturers |
Oral bisphosphonate |
Forteo’s principal market advantage is its long clinical history and established physician familiarity. Its disadvantages include daily injection, high historical pricing, prior safety restrictions and the availability of lower-priced teriparatide products.
What was Forteo’s financial trajectory?
Forteo revenue peaked before broad generic competition and then declined steadily. Eli Lilly’s reported revenue has been affected by U.S. generic entry, lower net pricing, international price controls and volume migration to competing therapies.
| Year |
Approximate Forteo revenue |
Main commercial driver |
| 2018 |
Approximately $1.5 billion |
Mature branded product before full generic impact |
| 2019 |
Approximately $1.4 billion |
Early generic and pricing pressure |
| 2020 |
Approximately $1.2 billion |
Generic competition and lower U.S. volume |
| 2021 |
Approximately $1.0 billion |
Continued generic substitution |
| 2022 |
Approximately $650 million |
Further price and volume erosion |
| 2023 |
Approximately $480 million to $550 million |
Mature-market decline and competitive pressure |
Figures are rounded from Eli Lilly annual reports and product-revenue disclosures. Lilly’s reporting methodology and geographic presentation can change between years, so year-to-year comparisons should be treated as directional rather than as a precise estimate of prescription-level market share (Eli Lilly and Company, 2019-2024).
Forteo’s decline has limited impact on Lilly’s current consolidated growth profile. The company’s diabetes, obesity and oncology products, particularly Mounjaro, Zepbound, Verzenio and Taltz, have become much larger revenue drivers. Forteo remains financially relevant as a recurring specialty-product franchise, but it is no longer a strategic growth engine.
When did Forteo lose exclusivity?
Forteo lost effective market exclusivity in the United States after expiration of its principal patent protection and resolution of generic-entry disputes. The core exclusivity period ended in the late 2010s, with commercial generic competition becoming meaningful around 2019-2020.
The product’s principal patent estate was based on teriparatide composition, manufacturing and related therapeutic claims. The core composition protection was not sufficient to prevent generic entry after the expiration period. Later formulation, device and method-of-use patents provided narrower protection and did not preserve the original branded pricing structure.
Forteo also benefited from regulatory exclusivity associated with its original FDA approval, but that period expired long before the current market phase. No meaningful orphan-drug exclusivity applies to Forteo.
What is the Orange Book status of Forteo?
Forteo was listed in the FDA Orange Book as a prescription drug product with patent information submitted by the innovator. The commercially important Orange Book protection has expired or no longer prevents approved generic teriparatide from entering the U.S. market.
The Orange Book remains relevant for:
- Identifying listed patents associated with the Forteo reference product
- Reviewing patent expiration dates
- Assessing whether an abbreviated new drug application used Paragraph IV certification
- Evaluating whether a later-listed device or formulation patent could support litigation
The current commercial issue is not whether Forteo has an unexpired core composition patent. It is whether remaining device, formulation or method-of-use claims can create a practical barrier to substitution. For teriparatide, those claims have not preserved the historical price premium.
Which companies challenged Forteo’s patent estate?
Generic manufacturers pursued U.S. abbreviated new drug applications for teriparatide injection and challenged or designed around Lilly’s remaining patent claims. Teva was among the most visible entrants in the U.S. teriparatide market. Other manufacturers and authorized or partner-distributed products expanded supply after the principal exclusivity period.
Patent disputes involving Forteo focused on the scope and enforceability of Lilly’s claims covering teriparatide formulations, manufacturing processes and use in osteoporosis. These disputes were commercially important because a successful challenge could accelerate entry, while a settlement could delay entry until an agreed date.
The market outcome indicates that Lilly did not maintain a durable patent-based exclusion after the late-2010s. Generic competition reached the U.S. market, and subsequent revenue erosion confirms that patent litigation did not preserve Forteo’s branded economics.
What generic entry risks exist for Forteo?
Generic entry risk is high in the United States and other developed markets.
The principal risks are:
- Price substitution. Teriparatide is clinically substitutable for many Forteo prescriptions, particularly when payer formularies treat products as equivalent.
- Medicare pressure. Osteoporosis patients are disproportionately covered by Medicare, where formulary placement and patient cost-sharing can shift use rapidly.
- Device competition. Generic manufacturers can compete through prefilled pen or pen-compatible delivery systems without replicating every element of Lilly’s commercial platform.
- Specialty-pharmacy control. Payers and pharmacy benefit managers can direct prescriptions toward lower-net-cost suppliers.
- International reference pricing. Lower prices in one jurisdiction can influence reimbursement negotiations elsewhere.
The main limitation on generic erosion is administration complexity. Teriparatide remains an injectable peptide product rather than a conventional small-molecule tablet. Manufacturing, analytical characterization, device integration and cold-chain or stability requirements can reduce the number of effective competitors. These barriers slow entry but do not create the high protection associated with a complex biologic.
Is Forteo exposed to biosimilar competition?
Forteo is not a conventional biologic subject to the standard biosimilar framework used for monoclonal antibodies and other large biologics. Teriparatide is a recombinant peptide and has generally entered the U.S. market through abbreviated generic-drug pathways rather than through the principal biosimilar pathway under the Public Health Service Act.
This distinction matters commercially:
- The regulatory pathway is generally less burdensome than for a large biologic.
- Generic teriparatide can produce faster price erosion than many injectable biologics.
- Device and formulation differences can still affect substitution.
- A product may be therapeutically comparable without receiving automatic pharmacy substitution in every jurisdiction.
The relevant competitive threat is therefore generic teriparatide, not biosimilar Forteo in the conventional regulatory sense.
What formulations and delivery systems protect Forteo?
Forteo’s original commercial differentiation included a multidose delivery pen designed for daily self-administration. Formulation and device claims have been strategically important because the active ingredient itself is no longer strongly protected.
Potentially relevant IP categories include:
- Teriparatide stability and storage formulations
- Multidose pen injectors
- Dose-delivery mechanisms
- Container-closure systems
- Manufacturing and purification processes
- Methods for treating specific osteoporosis populations
These rights can create litigation exposure for a generic entrant, but they are narrower than an active-ingredient patent. A competitor can often enter with a modified formulation, alternative device or different manufacturing process if it avoids valid claims.
For Forteo, the delivery system remains a practical commercial issue rather than a decisive exclusivity barrier. The product’s daily injection burden also gives monthly Evenity and less frequent antiresorptive products a convenience advantage.
How does Forteo compare with Tymlos and Evenity?
Forteo versus Tymlos
Forteo and Tymlos are both daily anabolic injectable therapies used for patients at high fracture risk. Tymlos contains abaloparatide, a synthetic analog of parathyroid hormone-related protein.
| Factor |
Forteo |
Tymlos |
| Active ingredient |
Teriparatide |
Abaloparatide |
| Administration |
Daily subcutaneous injection |
Daily subcutaneous injection |
| Commercial maturity |
Older, established brand and generic market |
Newer branded product |
| Generic exposure |
High |
Lower than Forteo during the relevant period |
| Physician familiarity |
Very high |
Growing |
| Key disadvantage |
Price erosion and daily dosing |
Smaller commercial scale and daily dosing |
Forteo’s generic availability has weakened its price position against Tymlos in some channels. Tymlos can command a branded premium, but it competes with a product that has broader historical use and greater physician familiarity.
Forteo versus Evenity
Evenity is administered monthly and has a different mechanism. It may provide a more convenient anabolic treatment option for selected high-risk patients, but cardiovascular safety considerations restrict its use in some patients.
Forteo remains attractive where clinicians prefer longer clinical experience with teriparatide or where Evenity is unsuitable because of cardiovascular risk. Evenity’s monthly administration and branded commercialization create a strong competitive challenge in treatment initiation.
What is the FDA regulatory status of Forteo?
Forteo remains FDA-approved and commercially available for its labeled osteoporosis indications. The 2020 label changes removed the boxed warning and lifetime treatment cap, subject to individualized clinical judgment.
The regulatory status supports continued use but does not create new market exclusivity. The FDA’s safety revisions may expand the eligible treatment duration for selected patients, yet generic competition means that additional duration primarily benefits the teriparatide category rather than Lilly’s branded product.
Lilly also developed and commercialized teriparatide products outside the original Forteo brand structure, including products intended to address lower-cost market segments. That strategy can preserve some value from manufacturing, regulatory and distribution capabilities while accepting erosion of the premium brand.
What litigation and settlement issues affect Forteo?
Forteo’s key litigation phase occurred before and around generic entry. The relevant disputes involved Paragraph IV certifications, patent validity, infringement and the timing of generic launches.
The commercial consequences were:
- Generic entrants gained a path to market.
- Lilly’s core exclusivity period ended without a durable secondary patent barrier.
- Any settlement value declined as multiple manufacturers and lower-priced products entered.
- Post-entry litigation risk shifted from blocking market access to managing formulation, device and method-of-use claims.
No current litigation outcome appears capable of restoring Forteo’s former monopoly economics. Any later dispute would be more likely to affect a specific product configuration than the entire teriparatide market.
What licensing deals affect Forteo?
Lilly retained the central commercial and regulatory rights to Forteo. The company has also used licensing, distribution and manufacturing arrangements for teriparatide-related products and regional markets.
The most important commercial change has been the transition from a single-originator model to a multi-supplier model. Licensing and partner arrangements can extend geographic reach or reduce manufacturing costs, but they do not replace expired composition patents.
The value of any Forteo-related deal is therefore likely to depend on:
- Manufacturing cost
- Regional reimbursement
- Existing regulatory approvals
- Device capabilities
- Supply reliability
- Access to government and specialty-pharmacy channels
How strong is the Forteo patent estate?
Forteo’s current patent estate is weak as a broad market-exclusion tool and moderate as a product-specific litigation tool.
| Patent category |
Current commercial strength |
| Core teriparatide composition |
Low after expiration |
| Manufacturing process |
Moderate if technically specific |
| Formulation and stability |
Moderate, but design-around risk exists |
| Injection pen and device |
Moderate for identical configurations |
| Broad method of use |
Low to moderate |
| Regulatory exclusivity |
Expired |
| Biosimilar barrier |
Not the primary framework |
Lilly’s strongest remaining defenses are likely to involve manufacturing know-how, device engineering, supply quality and physician familiarity. Those assets may support differentiated products, but they do not justify the historical Forteo price premium.
What generic launch scenarios exist for Forteo?
The likely market scenarios are:
| Scenario |
Market result |
| One or two generic suppliers |
Moderate price erosion; Lilly retains some branded demand |
| Multiple generic suppliers |
Rapid net-price decline and payer-directed substitution |
| Device-specific differentiation |
Fragmented market with limited automatic substitution |
| Strong payer preference for lowest cost |
Large volume migration away from Forteo |
| Clinical preference for branded product |
Slower erosion in specialist prescribing |
The most probable outcome is continued volume retention in selected patients alongside persistent revenue decline. Forteo may remain prescribed when physicians value brand familiarity, supply reliability or a specific pen configuration, but those factors are insufficient to reverse the mature-product trajectory.
Key Takeaways
- Forteo is Eli Lilly’s teriparatide product for high-risk osteoporosis patients.
- Revenue has fallen from approximately $1.5 billion in 2018 to roughly half a billion dollars by 2023.
- Core patent protection and regulatory exclusivity have expired.
- Generic teriparatide competition is the primary commercial threat, not conventional biosimilar competition.
- Teva and other manufacturers helped establish a lower-priced U.S. market.
- Device, formulation and manufacturing patents may support targeted disputes but do not recreate broad exclusivity.
- Tymlos competes directly as a daily anabolic therapy.
- Evenity competes through monthly dosing and a different anabolic mechanism.
- Forteo remains FDA-approved, but its regulatory position supports clinical availability rather than market protection.
- The financial trajectory is one of continued erosion, with limited strategic importance relative to Lilly’s newer growth products.
FAQs About Forteo Market Exclusivity and Commercial Risk
Does Forteo still have patent protection?
Forteo’s core composition protection has expired. Narrower formulation, device or manufacturing claims may remain relevant for specific products, but they do not prevent generic teriparatide competition broadly.
Is teriparatide interchangeable with Forteo?
Teriparatide products may be therapeutically comparable, but pharmacy-level substitution depends on FDA ratings, state law, payer policy and the specific delivery device.
Can Forteo revenue recover after the 2020 FDA label change?
The removal of the boxed warning and treatment-duration limitation supports broader clinical use, but generic pricing and competition limit the potential for a material branded revenue recovery.
Why is Forteo still prescribed despite generic competition?
Physicians may select Forteo because of its long clinical history, familiarity with its pen, perceived supply reliability or patient-specific treatment considerations.
What is the main long-term risk to Lilly from Forteo?
The principal risk is continued loss of branded volume and net price as payers steer prescriptions toward generic teriparatide and competing anabolic osteoporosis products.
References
Eli Lilly and Company. (2019-2024). Annual reports and Form 10-K filings. https://investor.lilly.com/financial-information/annual-reports
U.S. Food and Drug Administration. (2020). FDA approves new labeling for Forteo, removes boxed warning and lifetime use limitation. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024). Drugs@FDA: Forteo and teriparatide injection products. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (2024). Generic drug approvals and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-approvals-management-review-files-grants-and-tentative-approvals
